114 related articles for article (PubMed ID: 29433928)
1. Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerization.
Siddiqui-Jain A; Hoj JP; Cescon DW; Hansen MD
Bioorg Med Chem Lett; 2018 Mar; 28(5):934-941. PubMed ID: 29433928
[TBL] [Abstract][Full Text] [Related]
2. Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
Siddiqui-Jain A; Hoj JP; Hargiss JB; Hoj TH; Payne CJ; Ritchie CA; Herron SR; Quinn C; Schuler JT; Hansen MDH
Bioorg Med Chem Lett; 2017 Sep; 27(17):3992-4000. PubMed ID: 28780159
[TBL] [Abstract][Full Text] [Related]
3. Resistance mechanisms and cross-resistance for a pyridine-pyrimidine amide inhibitor of microtubule polymerization.
Fox JC; Evans AT; Blomfield MP; Livingstone SK; Tenney SR; Webster JB; Perry K; Hill JT; Bikman BT; Hansen MDH
Bioorg Med Chem Lett; 2019 Jul; 29(13):1647-1653. PubMed ID: 31047749
[TBL] [Abstract][Full Text] [Related]
4. The 3-D conformational shape of N-naphthyl-cyclopenta[d]pyrimidines affects their potency as microtubule targeting agents and their antitumor activity.
Xiang W; Quadery TM; Hamel E; Luckett-Chastain LR; Ihnat MA; Mooberry SL; Gangjee A
Bioorg Med Chem; 2021 Jan; 29():115887. PubMed ID: 33310545
[TBL] [Abstract][Full Text] [Related]
5. Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A(2B) adenosine receptor antagonists.
Eastwood P; Gonzalez J; Paredes S; Nueda A; Domenech T; Alberti J; Vidal B
Bioorg Med Chem Lett; 2010 Mar; 20(5):1697-700. PubMed ID: 20137946
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design and synthesis of bicyclic fused-pyridines as MEK inhibitors.
Lu H; Tu W; Fei H; Xu G; Hu Q; Zhang L; Lin B; Yuan J; Yin J; Gong A; Wan M; Wang D; Zhu X; Feng J; Wang Q; Sun P
Bioorg Med Chem Lett; 2014 Jun; 24(11):2555-9. PubMed ID: 24755426
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, and Preclinical Evaluation of 4-Substituted-5-methyl-furo[2,3-d]pyrimidines as Microtubule Targeting Agents That Are Effective against Multidrug Resistant Cancer Cells.
Devambatla RK; Namjoshi OA; Choudhary S; Hamel E; Shaffer CV; Rohena CC; Mooberry SL; Gangjee A
J Med Chem; 2016 Jun; 59(12):5752-65. PubMed ID: 27213719
[TBL] [Abstract][Full Text] [Related]
8. Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90.
Jiang F; Wang HJ; Jin YH; Zhang Q; Wang ZH; Jia JM; Liu F; Wang L; Bao QC; Li DD; You QD; Xu XL
J Med Chem; 2016 Dec; 59(23):10498-10519. PubMed ID: 27933959
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Zhang P; Dong J; Zhong B; Zhang D; Yuan H; Jin C; Xu X; Li H; Zhou Y; Liang Z; Ji M; Xu T; Song G; Zhang L; Chen G; Meng X; Sun D; Shih J; Zhang R; Hou G; Wang C; Jin Y; Yang Q
Bioorg Med Chem Lett; 2016 Apr; 26(8):1910-8. PubMed ID: 26979157
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the antitumor activity of NOV202, a novel microtubule targeting and vascular disrupting agent.
Rickardson L; Kutvonen E; Orasniemi S; Högberg M; Kallio MJ; Rehnmark S
Drug Des Devel Ther; 2017; 11():1335-1351. PubMed ID: 28496304
[TBL] [Abstract][Full Text] [Related]
11. YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo.
Cai D; Qiu Z; Yao W; Liu Y; Huang H; Liao S; Luo Q; Xie L; Lin Z
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1217-29. PubMed ID: 27107592
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
Zhu W; Wang W; Xu S; Wang J; Tang Q; Wu C; Zhao Y; Zheng P
Bioorg Med Chem; 2016 Apr; 24(8):1749-56. PubMed ID: 26964675
[TBL] [Abstract][Full Text] [Related]
13. New class of azaheptapyridine FPT inhibitors as potential cancer therapy agents.
Zhu HY; Desai J; Cooper AB; Wang J; Rane DF; Kirschmeier P; Strickland C; Liu M; Nomeir AA; Girijavallabhan VM
Bioorg Med Chem Lett; 2014 Feb; 24(4):1228-31. PubMed ID: 24462667
[TBL] [Abstract][Full Text] [Related]
14. Discovery of CYT997: a structurally novel orally active microtubule targeting agent.
Burns CJ; Harte MF; Bu X; Fantino E; Joffe M; Sikanyika H; Su S; Tranberg CE; Wilson N; Charman SA; Shackleford DM; Wilks AF
Bioorg Med Chem Lett; 2009 Aug; 19(16):4639-42. PubMed ID: 19616947
[TBL] [Abstract][Full Text] [Related]
15. N-(1'-naphthyl)-3,4,5-trimethoxybenzohydrazide as microtubule destabilizer: Synthesis, cytotoxicity, inhibition of cell migration and in vivo activity against acute lymphoblastic leukemia.
Salum LB; Mascarello A; Canevarolo RR; Altei WF; Laranjeira AB; Neuenfeldt PD; Stumpf TR; Chiaradia-Delatorre LD; Vollmer LL; Daghestani HN; de Souza Melo CP; Silveira AB; Leal PC; Frederico MJ; do Nascimento LF; Santos AR; Andricopulo AD; Day BW; Yunes RA; Vogt A; Yunes JA; Nunes RJ
Eur J Med Chem; 2015; 96():504-18. PubMed ID: 25951294
[TBL] [Abstract][Full Text] [Related]
16. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors.
Achary R; Yun JI; Park CM; Mathi GR; Lee JY; Ha JD; Chae CH; Ahn S; Park CH; Lee CO; Hwang JY; Yun CS; Jung HJ; Cho SY; Kim HR; Kim P
Bioorg Med Chem; 2016 Jan; 24(2):207-19. PubMed ID: 26712094
[TBL] [Abstract][Full Text] [Related]
18. A series of novel terpyridine-skeleton molecule derivants inhibit tumor growth and metastasis by targeting topoisomerases.
Kwon HB; Park C; Jeon KH; Lee E; Park SE; Jun KY; Kadayat TM; Thapa P; Karki R; Na Y; Park MS; Rho SB; Lee ES; Kwon Y
J Med Chem; 2015 Feb; 58(3):1100-22. PubMed ID: 25603122
[TBL] [Abstract][Full Text] [Related]
19. IRAK-4 inhibitors. Part 1: a series of amides.
Buckley GM; Gowers L; Higueruelo AP; Jenkins K; Mack SR; Morgan T; Parry DM; Pitt WR; Rausch O; Richard MD; Sabin V; Fraser JL
Bioorg Med Chem Lett; 2008 Jun; 18(11):3211-4. PubMed ID: 18474425
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of novel trifluoromethyl substituted furo[2,3-b]pyridine and pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as potential anticancer agents.
Naresh Kumar R; Poornachandra Y; Nagender P; Mallareddy G; Ravi Kumar N; Ranjithreddy P; Ganesh Kumar C; Narsaiah B
Eur J Med Chem; 2016 Jan; 108():68-78. PubMed ID: 26629861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
